Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon2 hr ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsAviationArtificial IntelligencePublishers

Trump, ibogaine and the science behind the psychedelics boom in the U.S.

1 articles · 1 outlets · spread 0.00

Trump, ibogaine and the science behind the psychedelics boom in the U.S.
psychedelics2 d ago

Trump, ibogaine and the science behind the psychedelics boom in the U.S.

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • Scientific American·May 1

    Trump, ibogaine and the science behind the psychedelics boom in the U.S.

    Rachel Feltman: For Scientific American’s Science Quickly, I’m Rachel Feltman.For years when most people thought about psychedelic drugs, they pictured long-haired tripping hippies either having a ball or risking and wasting their lives, depending on the tenor of the anti-drug messaging one happened to be subject to. That association was cemented in the late 1960s, when modern scientific study of psychedelics—which had been picking up speed since the ’50s—ground to a halt, thanks to government regulation and negative public opinion. But when science ceded psychedelics to the counterculture movement, it abandoned promising results on the power of these drugs to change human minds for the better.Then, at the turn of the 21st century, Johns Hopkins University received the first regulatory approval to resume the study of psychedelics in the U.S. The university’s research kicked off a full-blown psychedelics renaissance, putting a spotlight on MDMA, psilocybin and other drugs previously known for their recreational effects as potential treatments for post-traumatic stress disorder, depression, substance-use disorder and more.On supporting science journalismIf you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

Scientific American

First seen

May 1, 2026

Latest

May 1, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.